[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2007088276A3 - Derives de sulfonamides, leur preparation et leur application en therapeutique - Google Patents

Derives de sulfonamides, leur preparation et leur application en therapeutique Download PDF

Info

Publication number
WO2007088276A3
WO2007088276A3 PCT/FR2007/000182 FR2007000182W WO2007088276A3 WO 2007088276 A3 WO2007088276 A3 WO 2007088276A3 FR 2007000182 W FR2007000182 W FR 2007000182W WO 2007088276 A3 WO2007088276 A3 WO 2007088276A3
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
preparation
several groups
sulfonamide derivatives
therapeutic application
Prior art date
Application number
PCT/FR2007/000182
Other languages
English (en)
Other versions
WO2007088276A2 (fr
Inventor
Gilles Courtemanche
Pierre Despeyroux
Evelyne Fontaine
Pierrick Rochard
Gal Claudine Serradeil-Le
Roedern Erich Von
Original Assignee
Sanofi Aventis
Gilles Courtemanche
Pierre Despeyroux
Evelyne Fontaine
Pierrick Rochard
Gal Claudine Serradeil-Le
Roedern Erich Von
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis, Gilles Courtemanche, Pierre Despeyroux, Evelyne Fontaine, Pierrick Rochard, Gal Claudine Serradeil-Le, Roedern Erich Von filed Critical Sanofi Aventis
Priority to EP07730899A priority Critical patent/EP1981842A2/fr
Priority to JP2008552847A priority patent/JP2009525312A/ja
Publication of WO2007088276A2 publication Critical patent/WO2007088276A2/fr
Publication of WO2007088276A3 publication Critical patent/WO2007088276A3/fr
Priority to US12/183,487 priority patent/US20090054439A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention a pour objet des dérivés de sulfonamides répondant à la formule générale (I) : Ar1 représente un aryle éventuellement substitué par un ou plusieurs groupes, un groupe hétérocyclyle, éventuellement substitué ; T représente un -(CH2)n- ou un groupe Ar2 représente un aryle éventuellement substitué par un ou plusieurs groupes, un groupe hétérocyclyle éventuellement substitué ; Ar3 représente un aryle, éventuellement substitué par un ou plusieurs groupes, ou bien un hétérocyclyle éventuellement substitué ; R représentent un hydrogène ou un (C1-C4) alkyle; R' représente un (C1-C4) alkyle éventuellement substitué; un acide carboxylique, un (C1-C4) carboxylate, une carboxamide éventuellement substitué; à l'état de base, de sel d'addition à un acide, d'hydrate ou de solvat, sous forme d'énantiomères, de diastéréoisomères, de rotamères, d'atropoisomères ou de leurs mélanges. Elle concerne également le procédé de préparation ainsi que l'utilisation en thérapeutique des composés de formule (I).
PCT/FR2007/000182 2006-02-02 2007-02-01 Derives de sulfonamides, leur preparation et leur application en therapeutique WO2007088276A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP07730899A EP1981842A2 (fr) 2006-02-02 2007-02-01 Derives de sulfonamides, leur preparation et leur application en therapeutique
JP2008552847A JP2009525312A (ja) 2006-02-02 2007-02-01 スルホンアミド誘導体、これの調製および治療への応用
US12/183,487 US20090054439A1 (en) 2006-02-02 2008-07-31 Sulfonamide derivatives, preparation and therapeutic application thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0600955A FR2896799B1 (fr) 2006-02-02 2006-02-02 Derives de sulfonamides, leur preparation et leur application en therapeutique
FR0600955 2006-02-02

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/183,487 Continuation US20090054439A1 (en) 2006-02-02 2008-07-31 Sulfonamide derivatives, preparation and therapeutic application thereof

Publications (2)

Publication Number Publication Date
WO2007088276A2 WO2007088276A2 (fr) 2007-08-09
WO2007088276A3 true WO2007088276A3 (fr) 2007-10-25

Family

ID=37499618

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2007/000182 WO2007088276A2 (fr) 2006-02-02 2007-02-01 Derives de sulfonamides, leur preparation et leur application en therapeutique

Country Status (5)

Country Link
US (1) US20090054439A1 (fr)
EP (1) EP1981842A2 (fr)
JP (1) JP2009525312A (fr)
FR (1) FR2896799B1 (fr)
WO (1) WO2007088276A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
RS59004B1 (sr) 2009-10-23 2019-08-30 Janssen Pharmaceutica Nv Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
WO2012120054A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120055A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
EP2683700B1 (fr) 2011-03-08 2015-02-18 Sanofi Dérivés d'oxathiazine tétra-substitués, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120053A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
BR112014019426A8 (pt) 2012-02-07 2017-07-11 Eolas Therapeutics Inc Prolinas/ piperidinas substituídas como antagonistas do receptor de orexina
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
US10221170B2 (en) 2014-08-13 2019-03-05 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
LT3414241T (lt) 2016-02-12 2022-08-25 Astrazeneca Ab Halogenu pakeisti piperidinai kaip oreksino receptoriaus moduliatoriai
CN115154470B (zh) 2016-03-10 2024-09-20 詹森药业有限公司 使用食欲素-2受体拮抗剂治疗抑郁症的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0358571A1 (fr) * 1988-09-08 1990-03-14 Pierre Fabre Medicament Thioformamidines, leur préparation et leur application en tant que médicaments
US20060014783A1 (en) * 2002-10-11 2006-01-19 Hamed Aissaoui Sulfonylamino-acetic acid derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2548400A (en) 1999-02-12 2000-08-29 Smithkline Beecham Plc Novel use of orexin receptor antagonists
DE60013250T2 (de) * 1999-02-12 2005-09-08 Smithkline Beecham P.L.C., Brentford Phenylharnstoff- und Phenylthioharnstoffderivate als Orexinrezeptorantagonisten
CA2423792A1 (fr) * 2000-10-20 2002-04-25 Pfizer Products Inc. Ethanolamines alpha-aryle et utilisation de ces dernieres en tant qu'agonistes du recepteur adrenergique beta-3
HUP0304101A3 (en) * 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
HUP0400405A3 (en) * 2004-02-10 2009-03-30 Sanofi Synthelabo Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
FR2874011B1 (fr) * 2004-08-03 2007-06-15 Sanofi Synthelabo Derives de sulfonamides, leur preparation et leur application en therapeutique

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0358571A1 (fr) * 1988-09-08 1990-03-14 Pierre Fabre Medicament Thioformamidines, leur préparation et leur application en tant que médicaments
US20060014783A1 (en) * 2002-10-11 2006-01-19 Hamed Aissaoui Sulfonylamino-acetic acid derivatives

Also Published As

Publication number Publication date
WO2007088276A2 (fr) 2007-08-09
US20090054439A1 (en) 2009-02-26
FR2896799B1 (fr) 2008-03-28
FR2896799A1 (fr) 2007-08-03
JP2009525312A (ja) 2009-07-09
EP1981842A2 (fr) 2008-10-22

Similar Documents

Publication Publication Date Title
WO2007088276A3 (fr) Derives de sulfonamides, leur preparation et leur application en therapeutique
TW200738607A (en) Sulfonamide derivatives, preparation thereof and therapeutic use thereof
MXPA05004188A (es) Antagonistas de cgrp elegidos, procedimiento para su preparacion, asi como su empleo como medicamentos.
RS20050311A (en) Selected cgrp antagonists,method for production and use thereof as medicament
WO2005103037A3 (fr) Antagonistes du cgrp selectionnes, procedes de production de ces antagonistes et leur utilisation comme medicaments
WO2006113552A3 (fr) Cyanoarylamines
ATE406360T1 (de) Antagonisten der opioidrezeptoren
WO2004096134A3 (fr) 1,4-diazepines substituees et leurs utilisations
TW200728307A (en) Novel spirochromanone derivatives
EA200970149A1 (ru) Производные n-(аминогетероарил)-1h-индол-2-карбоксамидов, их получение и их применение в терапии
SI2091948T1 (sl) Novi inhibitorji glutaminil ciklaze
EA200501477A1 (ru) Производные пиперидинил- и пиперазинилалкилкарбаматов, способы их получения и применение их в терапии
WO2007032028A8 (fr) Thiazolinones et oxazolinones et leur utilisation en tant qu'inhibiteurs de ptp1b
TW200609204A (en) Sulfonamide derivatives, preparation thereof and therapeutic application thereof
MX2009003739A (es) Derivados de hidrobenzamida como inhibidores de hsp90.
NO20072515L (no) 2-amido-4-fenyltnazolderivater, fremstilling og terapeutsik anvendelse derav
WO2005087771A3 (fr) 5,6-dialkyl-7-amino-triazolopyrimidines, procedes pour leur production, leur utilisation pour lutter contre des champignons nuisibles, ainsi qu'agents les contenant
ECSP067111A (es) Derivados de pirido-pirimidina, su preparación, su aplicación en terapéutica
WO2009150381A3 (fr) Derives d'azacarbolines, leur preparation et leur utilisation therapeutique en tant qu'inhibiteurs de kinases
SE0403171D0 (sv) New compounds
NO985518L (no) Morfinanderivater og medisinsk anvendelse derav
MX2007007105A (es) Procedimiento para la preparacion de un derivado de 2-piridiletilcarboxamida.
MX2010003849A (es) Antagonistas de cgrp.
RS20060239A (en) Arylalkylcarbamate derivatives, preparation method thereof and use of same in therapeutics
EA200301120A1 (ru) Цитрат 5,8,14-триазатетрацикло (10.3.1.0.0)-гексадека-2 (11),3,5,7,9-пентаена

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2007730899

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008552847

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE